The FDA has approved Norditropin (somatropin [rDNA origin] injection, from Novo Nordisk) for the treatment of children with short stature born small for gestational age (SGA) with no catch-up growth by ages 2–4 years. This approval was based on data from a 13-year clinical trial that showed 63% of Norditropin-treated children who reached adult height were in the normal range of their peers.

Norditropin is already indicated for the treatment of children with short stature associated with Noonan and Turner syndrome, growth failure in children due to inadequate growth hormone (GH), and adults with childhood- or adult-onset GH deficiency.

For more information call (888) 668-6444 or visit www.norditropin-us.com.